Treatment Logic Agent

The supplied document contains treatment-cycle and interruption rules for BESPONSA in relapsed or refractory acute lymphoblastic leukemia, including cycle start timing, dose scheduling, interruption thresholds, and hematopoietic stem cell transplant (HSCT) considerations. It states that "Cycle 1 is 3 weeks in duration, but may be extended to 4 weeks if the patient achieves a complete remission (CR) or complete remission with incomplete hematologic recovery (CRi), and/or to allow recovery from toxicity," and that subsequent cycles are "4 weeks in duration." The document also specifies interruption and discontinuation logic, including that clinicians should "interrupt the next cycle of treatment until recovery" for specified hematologic toxicities and that "Greater than 28 days" of interruption may require to "Consider permanent discontinuation of treatment." For HSCT handling, it states that "For patients proceeding to hematopoietic stem cell transplant (HSCT), the recommended duration of treatment with BESPONSA is 2 cycles," with a possible third cycle under defined response conditions. The document does not provide United States claims-data operational algorithms for constructing lines of therapy, including regimen-level line advancement triggers, treatment-gap definitions in claims data, maintenance handling, relapse/re-treatment episode construction, or claims-based transplant episode logic. The supplied document does not describe United States claims-data algorithms for constructing lines of therapy in Acute Lymphoblastic Leukemia, including regimen start/stop logic, line advancement triggers, treatment gaps, maintenance handling, stem-cell transplant episode handling, or relapse/retreatment operational rules. It only provides BLINCYTO treatment-cycle schedules and interruption rules that mention induction, consolidation, continued therapy, treatment-free intervals, and restarting cycles after interruptions. Specifically, the document states that induction and consolidation cycles are "28 days of continuous intravenous infusion followed by a 14-day treatment-free interval," while "continued therapy consists of 28 days of continuous intravenous infusion followed by a 56-day treatment-free interval." It also states that "If the interruption after an adverse reaction is no longer than 7 days, continue the same cycle," but "If an interruption due to an adverse reaction is longer than 7 days, start a new cycle."

The supplied documents do not provide a comprehensive United States claims-based regimen library for Acute Lymphoblastic Leukemia (ALL), and they do not enumerate induction, consolidation, intensification, maintenance, or detailed multi-agent regimen sequencing groupings and aliases. The documents do identify several ALL-related therapeutic agents and cellular therapies that may appear in regimen libraries, including “rituximab,” “blinatumomab,” “inotuzumab ozogamicin,” “vincristine sulfate,” “doxorubicin hydrochloride,” “cyclophosphamide,” “methotrexate sodium,” “cytarabine,” “daunorubicin hydrochloride,” “Tisagenlecleucel CAR-T,” and “Brexucabtagene autoleucel CAR-T.” The transplantation-related document states that “Allogeneic SCT is recommended for children who: are in second complete remission (CR2) after experiencing an early marrow relapse for precursor-B ALL; experienced primary induction failure, but subsequently achieved a CR1; have T-lineage ALL in CR2; or have ALL in third or greater remission,” and also notes that “chemotherapy + imatinib” had outcomes “comparable for allogeneic SCT.” No document supplies standardized regimen aliases, naming conventions, or component-grouping rules for treatment sequencing analyses. The supplied documents do not provide a comprehensive United States clinical practice or claims-based regimen library for Acute Lymphoblastic Leukemia (ALL), and they do not enumerate induction, consolidation, intensification, maintenance, or treatment-sequencing regimen groupings and aliases. The documents do identify several therapies used in relapsed or refractory ALL and transplant-related settings, including "blinatumumab," "inotuzumab," and "CAR-T cells," and they discuss "bridging therapy prior to reinjection of autologous CAR-T cells" in relapsed/refractory B-ALL. The FDA Purple Book document lists product and generic names relevant for alias grouping, including "Blincyto blinatumomab," "Besponsa inotuzumab ozogamicin," "Kymriah tisagenlecleucel," "Tecartus brexucabtagene autoleucel," "Aucatzyl obecabtagene autoleucel," and rituximab biosimilars such as "Truxima rituximab-abbs," "Ruxience rituximab-pvvr," and "Riabni rituximab-arrx." The transplant-focused guideline also states that "post-transplantation tyrosine kinase inhibitors as a systematic maintenance strategy is recommended" for Philadelphia chromosome positive ALL, but no specific multi-agent maintenance regimen compositions or sequencing rules are provided. The supplied documents identify only limited Acute Lymphoblastic Leukemia regimens and do not provide a comprehensive U.S. clinical practice or claims-based regimen library across induction, consolidation, intensification, maintenance, relapsed/refractory, and transplant-related settings through 2026-09-21. For relapsed or refractory Ph+ ALL, dasatinib (SPRYCEL) is indicated for “adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy,” and imatinib is indicated for “Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL).” The documents also note a pediatric Ph+ ALL combination approach where “Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy” may receive imatinib, but no specific chemotherapy backbone, induction, consolidation, maintenance, intensification, transplant-related regimen definitions, aliases, or component-grouping rules are provided. The supplied documents describe broad United States clinical practice guidance for ALL but do not provide the detailed claims-based regimen library, regimen-component grouping rules, aliases, or exhaustive multi-agent regimen names requested for sequencing analyses. The documents state that ALL management includes “risk-stratified treatment approaches,” “more intensive chemotherapy regimens, tyrosine kinase inhibitors, targeted agents, and allogeneic hematopoietic cell transplantation,” and that “Pediatric-inspired regimens containing asparaginase are recommended as frontline therapy compared with more traditional adult-inspired protocols.” The relapsed or refractory setting is specifically referenced, with NCCN updates that “summarize treatment recommendations for R/R ALL.” Transplant-related management is also referenced, including that “Allogeneic hematopoietic stem cell transplantation is not routinely recommended in first remission but may be indicated for higher-risk subsets or those with suboptimal responses to initial therapy.” The documents do identify several treatment settings and regimen elements: relapsed/refractory management recommendations include “the use of blinatumomab and/or inotuzumab over chemotherapy for reinduction,” with discussion of “consolidation with allogeneic transplant” and “CNS-directed therapy.” The documents also describe “asparaginase-containing regimens” and “pediatric/pediatric-inspired regimens incorporating asparaginase” used in AYA and adult ALL populations. Maintenance therapy is described as “the last phase of treatment for acute lymphoblastic leukemia in children and adolescents,” but no specific multi-agent maintenance regimen components, aliases, or grouping conventions are supplied. The supplied documents only partially address Acute Lymphoblastic Leukemia regimens and do not provide a comprehensive United States claims-based regimen library across induction, consolidation, intensification, maintenance, relapsed/refractory, transplant-related settings, or regimen alias grouping rules. The documents identify methotrexate as being used "as part of a combination chemotherapy maintenance regimen" for ALL, clofarabine for "relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens," and imatinib mesylate for "Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL)" and for "Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy." No induction, consolidation, intensification, transplant-conditioning regimens, sequencing logic, component grouping methodology, or regimen aliases are described in the supplied documents. The supplied documents do not provide a United States claims-based ALL regimen library, treatment-sequencing grouping rules, or comprehensive induction, consolidation, intensification, maintenance, transplant-related, or regimen-alias mappings. The only explicit relapsed/refractory regimen-related information is that nelarabine is indicated for "T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL)" in patients "whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens." The documents also describe a nelarabine administration schedule in relapsed/refractory T-ALL/T-LBL clinical trials: "1,500 mg/m 2 of Nelarabine Injection Administered Intravenously Over 2 Hours on Days 1, 3, and 5 Repeated Every 21 Days." No source text defines how regimen components or aliases should be grouped for sequencing analyses. The supplied documents only identify limited Acute Lymphoblastic Leukemia (ALL) treatment settings and do not provide a comprehensive U.S. claims-based regimen library through 2026-09-21. For relapsed or refractory ALL, BESPONSA (inotuzumab ozogamicin) is indicated for "relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adult and pediatric patients 1 year and older." For maintenance therapy, methotrexate tablets are indicated for the "treatment of adults and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen." The documents do not describe induction regimens, consolidation regimens, intensification regimens, transplant-conditioning regimens, regimen component grouping rules, or regimen aliases/naming conventions for treatment sequencing analyses. The supplied documents identify only limited Acute Lymphoblastic Leukemia (ALL) regimen information. Methotrexate labeling states that it is used for ALL "as part of a combination chemotherapy regimen" and for "prophylaxis and treatment of meningeal leukemia," but no induction, consolidation, intensification, maintenance, transplant-related, or sequencing regimen library definitions are provided. Imatinib and dasatinib labeling identify Philadelphia chromosome-positive ALL settings, including "relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL)," "newly diagnosed Ph+ ALL in combination with chemotherapy," and "Ph+ ALL with resistance or intolerance to prior therapy," but the documents do not define multi-agent regimen names, aliases, component grouping rules, or claims-based sequencing conventions. The supplied documents identify that NCCN ALL guidelines address treatment strategies and management settings for adult and pediatric acute lymphoblastic leukemia, including “risk-adapted therapy,” “frontline and relapsed/refractory management,” “hematopoietic stem cell transplantation,” and management of “BCR::ABL1-positive” and “BCR::ABL1-negative” disease. However, the documents provided do not enumerate specific multi-agent induction, consolidation, intensification, maintenance, relapsed/refractory, or transplant-related regimens, nor do they provide claims-based regimen library conventions, component grouping rules, aliases, or treatment-sequencing nomenclature. Therefore, the requested regimen lists, aliases, and grouping logic for sequencing analyses cannot be fully derived from the supplied text. The supplied documents only identify two Acute Lymphoblastic Leukemia treatment contexts and do not provide a comprehensive United States claims-based regimen library through 2026-09-21. For relapsed or refractory ALL, clofarabine is indicated "for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens." For maintenance therapy, mercaptopurine is indicated "for the treatment of patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen." The documents do not list specific induction, consolidation, intensification, transplant-related multi-agent regimens, regimen aliases, or component-grouping rules for treatment sequencing analyses. The supplied documents do not provide a United States ALL regimen library through 2026-09-21 and do not enumerate induction, consolidation, intensification, maintenance, transplant-related, or regimen-alias grouping frameworks for treatment sequencing analyses. The documents only identify selected agents and limited usage context in ALL, including that methotrexate is used in ALL "as part of a combination chemotherapy regimen" and for "prophylaxis and treatment of meningeal leukemia." The documents also identify FDA products relevant to ALL care, including ICLUSIG (ponatinib) and ARRANON (nelarabine), but they do not describe multi-agent regimens, regimen naming conventions, or component-grouping logic. The supplied document only states that doxorubicin hydrochloride is indicated for treatment of "acute lymphoblastic leukemia" and that it may be used "in combination with other chemotherapy drugs." It does not provide United States ALL regimen libraries, induction, consolidation, intensification, maintenance, relapsed/refractory, transplant-related regimens, or guidance on regimen component grouping, aliases, or treatment sequencing analyses. Therefore, the requested regimen-level details are not available in the provided materials. The supplied documents identify the major treatment phases for Acute Lymphoblastic Leukemia (ALL), including induction chemotherapy, consolidation therapy, maintenance therapy, CNS prophylaxis, treatment of mature B-cell ALL, treatment of Philadelphia chromosome–positive ALL, and treatment of younger adults, but they do not provide a complete claims-oriented regimen library or detailed multi-agent regimen component mappings and aliases for sequencing analyses. The documents also do not enumerate specific regimen names, standardized aliases, component-grouping rules, transplant-conditioning regimens, or relapsed/refractory regimen taxonomies. Therefore, the available material only partially addresses the requested scope.

The supplied documents identify several Acute Lymphoblastic Leukemia regimen component drugs and branded products, but they do not provide HCPCS codes, J-codes, CPT drug-administration codes, NDC mappings, biosimilar mappings, or multi-source generic mappings. Clofarabine injection is described as "indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens." Imatinib mesylate is described for "Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL)" and for "Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy." The Drugs@FDA record identifies the branded product SPRYCEL with multiple tablet strengths, but no claims-code mappings or administration linkages are provided. The supplied documents provide HCPCS/J-code mappings for several Acute Lymphoblastic Leukemia regimen component drugs used in treatment sequencing analyses, including rituximab (J9312), blinatumomab (J9039), inotuzumab ozogamicin (J9229), vincristine sulfate (J9370), doxorubicin hydrochloride (J9000), cyclophosphamide (J9070), methotrexate sodium (J9250 and J9260), cytarabine (J9100), daunorubicin hydrochloride (J9150), tisagenlecleucel (Q2042), and brexucabtagene autoleucel (Q2053). The documents also specifically confirm that HCPCS code J9039 corresponds to “Injection, blinatumomab, 1 microgram” and HCPCS code J9229 corresponds to “Injection, inotuzumab ozogamicin, 0.1 mg.” However, the supplied documents do not provide NDC mappings, biosimilar mappings, multi-source generic mappings beyond the named generic ingredients, or CPT drug-administration code linkage. The documents identify imatinib mesylate tablets for "Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL)" and for "Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy." They also identify clofarabine injection "for intravenous use" for pediatric relapsed/refractory ALL and methotrexate injection "for intravenous, intramuscular, subcutaneous, or intrathecal use" for ALL as part of combination chemotherapy regimens. The supplied documents identify regimen component drugs used in Acute Lymphoblastic Leukemia (ALL) treatment contexts, specifically methotrexate and clofarabine, but they do not provide HCPCS codes, J-codes, CPT drug-administration codes, NDC mappings, biosimilar mappings, or multi-source generic mapping tables. Methotrexate labeling states it is indicated for "treatment of adults and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen." Clofarabine labeling states it is indicated for "pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens." No claims-code linkage or administration-code mapping information is present in the documents. The supplied documents identify several Acute Lymphoblastic Leukemia regimen component products and some HCPCS mappings, including branded products and rituximab biosimilars. The FDA Purple Book rows list "Rituxan rituximab," "Blincyto blinatumomab," "Besponsa inotuzumab ozogamicin," "Kymriah tisagenlecleucel," "Tecartus brexucabtagene autoleucel," "Aucatzyl obecabtagene autoleucel," and biosimilars "Truxima rituximab-abbs (biosimilar to Rituxan)," "Ruxience rituximab-pvvr (biosimilar to Rituxan)," and "Riabni rituximab-arrx (biosimilar to Rituxan)." The HCPCS tables map tisagenlecleucel to HCPCS codes Q2040 and Q2042 with detailed code descriptions. The documents do not provide NDC mappings, J-codes, CPT drug-administration codes, or multi-source generic mappings. The documents state that SPRYCEL (dasatinib) is indicated for “Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy.” They also identify branded products relevant to leukemia treatment sequencing analyses, including “ICLUSIG TABLET ORAL” in multiple strengths and “ARRANON INJECTABLE INTRAVENOUS strength 250MG/50ML (5MG/ML).” No administration code linkage or claims-code crosswalks are provided in the supplied material. The supplied documents identify several regimen component drugs and treatment contexts for Acute Lymphoblastic Leukemia (ALL), including BESPONSA (inotuzumab ozogamicin), BLINCYTO (blinatumomab), KYMRIAH (tisagenlecleucel), and comparator chemotherapy regimens containing fludarabine, cytarabine, mitoxantrone, granulocyte colony-stimulating factor, and high-dose cytarabine. However, the documents do not provide HCPCS codes, J-codes, CPT drug-administration codes, NDC mappings, biosimilar mappings, or multisource generic mappings. The documents also describe administration modality for BLINCYTO and KYMRIAH, including intravenous infusion and continuous IV infusion schedules, but no billing-code linkage is provided. The supplied documents identify regimen component drugs used for Acute Lymphoblastic Leukemia treatment analyses, including doxorubicin hydrochloride and methotrexate sodium formulations, and include branded and multi-source generic injectable product descriptions. However, the documents do not provide HCPCS codes, J-codes, CPT drug-administration codes, biosimilar mappings, or NDC mappings. The documents do provide evidence that doxorubicin hydrochloride is indicated for “acute lymphoblastic leukemia” and list multiple methotrexate injectable product variants and preservative-free formulations that could correspond to generic product mapping exercises in claims-based sequencing analyses. The supplied documents provide limited NDC mapping information for dasatinib products relevant to Acute Lymphoblastic Leukemia treatment sequencing analyses. Documented products include Biocon Pharma Inc. ANDA dasatinib tablet products with NDC package identifiers "70377-087-11" and "70377-088-11" for 100 mg and 140 mg strengths, respectively, and a Prasco Laboratories "NDA AUTHORIZED GENERIC" dasatinib 20 mg tablet product with package identifier "66993-233-60." The documents identify these as generic or authorized generic oral products, but they do not provide HCPCS codes, J-codes, CPT drug-administration linkage, biosimilar mappings, or broader multi-source generic mappings. The supplied documents provide limited HCPCS/J-code mappings for several Acute Lymphoblastic Leukemia treatment components. Documented mappings include HCPCS code C9449 for blinatumomab defined as "Injection, blinatumomab, 1 mcg," HCPCS code C9028 for inotuzumab ozogamicin defined as "Injection, inotuzumab ozogamicin, 0.1 mg," and HCPCS code Q2053 for brexucabtagene autoleucel defined as "up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose." The documents do not provide NDC mappings, biosimilar mappings, multi-source generic mappings, or CPT drug-administration code linkages. The supplied documents identify doxorubicin (Adriamycin/DOXOrubicin HCl) as a regimen component drug used for treatment of acute lymphoblastic leukemia and describe intravenous administration details, but they do not provide HCPCS codes, J-codes, CPT drug-administration codes, NDC mappings, biosimilar mappings, or multi-source generic coding crosswalks. The labels state that "Doxorubicin is indicated for the treatment of acute lymphoblastic leukemia" and describe administration "as an intravenous injection" and dosing in "combination with other chemotherapy drugs." No claims-data coding mappings or administration billing code linkages are present in the documents. The documents do establish branded/generic drug identities and ALL-related treatment use cases: nelarabine injection for relapsed or refractory T-ALL/T-LBL, dasatinib tablets for Ph+ ALL, and mercaptopurine oral suspension for ALL maintenance therapy. No administration-code linkage or claims-code crosswalks are present in the supplied materials. The supplied documents provide limited NDC mappings for branded oral ALL therapies, specifically SPRYCEL (dasatinib) and Iclusig (ponatinib hydrochloride). Document 0 identifies SPRYCEL with package NDC "0003-0524-11" and active ingredient "DASATINIB 70 mg/1," while Document 1 identifies SPRYCEL with package NDC "0003-0857-22" and active ingredient "DASATINIB 140 mg/1." Document 2 identifies Iclusig with package NDC "63020-533-30" and active ingredient "PONATINIB HYDROCHLORIDE 30 mg/1." The documents do not provide HCPCS codes, J-codes, CPT drug-administration codes, biosimilar mappings, generic product mappings, or treatment sequencing linkage information. The documents provide limited NDC mappings for several Acute Lymphoblastic Leukemia regimen component drugs, including branded and generic products, but they do not provide HCPCS, J-code, CPT drug-administration, biosimilar linkage, or treatment sequencing analysis mappings. Documented NDC products include Clofarabine injection marketed as an ANDA generic with package code 43598-309-20, Arranon (nelarabine) intravenous injection with package code 66758-165-94, and Dasatinib oral tablets with package code 70377-085-11. The supplied records identify product names, active ingredients, dosage forms, package identifiers, and marketing categories only. The supplied documents provide limited mappings for regimen component drugs relevant to Acute Lymphoblastic Leukemia claims analyses. HCPCS mapping is available for imatinib: HCPCS code S0088 is defined as “Imatinib 100 mg — Imatinib, 100 mg.” NDC mappings are provided for branded and generic kinase inhibitors, including IMKELDI (imatinib oral solution) with NDC 81927-201-01 and an authorized generic dasatinib product with NDC 66993-234-60. The documents do not provide CPT drug-administration code linkage, biosimilar mappings, or broader multisource generic mapping tables beyond the specific examples shown. The supplied documents provide limited mappings relevant to Acute Lymphoblastic Leukemia treatment sequencing analyses. HCPCS mappings are provided for obecabtagene autoleucel under codes C9301 and Q2058, including descriptions of the leukapheresis and infusion-related therapeutic dose definitions. An NDC mapping is provided for Arranon (nelarabine) intravenous injection under NDC 0078-0683-61 with active ingredient nelarabine 5 mg/mL. The documents do not provide broader HCPCS/J-code mappings, CPT drug-administration linkage, biosimilar mappings, or multi-source generic mappings beyond these examples. The supplied documents only provide partial NDC mapping information for dasatinib generic products and do not provide HCPCS, J-code, CPT drug-administration, biosimilar, or treatment-sequencing linkage information. The documents identify Biocon Pharma Inc. oral dasatinib tablet products with NDC package identifiers 70377-083-11 (20 mg), 70377-084-11 (50 mg), and 70377-086-11 (80 mg), each with marketing category "ANDA," indicating generic products. No branded-product mappings, biosimilar mappings, HCPCS/J-codes, or administration code linkages are present in the supplied material. The documents provide NDC mappings for the branded product Iclusig (ponatinib hydrochloride), including multiple strengths and package configurations. Specifically, NDC 63020-534 corresponds to 45 mg tablets, NDC 63020-536 corresponds to 10 mg tablets, and NDC 63020-535 corresponds to 15 mg tablets with both 30-count and 60-count bottle presentations. The supplied documents do not provide HCPCS codes, J-codes, CPT drug-administration codes, biosimilar mappings, or multi-source generic mappings for treatment sequencing analyses. A HCPCS mapping is provided for brexucabtagene autoleucel under code C9073, and NDC mappings are provided for branded SPRYCEL (dasatinib) oral tablets with NDC package identifiers 0003-0855-22 and 0003-0528-11. The documents do not provide CPT drug-administration linkage, biosimilar mappings, multi-source generic mappings, or broader treatment sequencing mappings through 2026-09-21.

The documents identify oral and intravenous ALL therapies, but they do not discuss United States claims adjudication under pharmacy versus medical benefit, dual-channel billing, or line-of-therapy routing ambiguities. SPRYCEL (dasatinib) for Philadelphia chromosome-positive acute lymphoblastic leukemia is described as an oral tablet therapy: "SPRYCEL TABLET ORAL" and "The recommended starting dosage of SPRYCEL for accelerated phase CML, myeloid or lymphoid blast phase CML, or Ph+ ALL is 140 mg administered orally once daily." KYMRIAH (tisagenlecleucel) for relapsed or refractory B-cell ALL is described as "suspension for intravenous infusion" and as a "CD19-directed genetically modified autologous T cell immunotherapy." The supplied documents do not state whether these products are adjudicated through pharmacy or medical benefits, nor do they describe benefit-routing ambiguities or dual-channel billing patterns affecting line-of-therapy construction. The supplied documents identify several Acute Lymphoblastic Leukemia (ALL) therapies and specify that they are administered intravenously, but they do not explicitly describe adjudication under pharmacy versus medical benefits, dual-channel billing, or claims-routing ambiguities. BLINCYTO (blinatumomab) is described as “for injection, for intravenous use,” and is indicated for multiple ALL settings including “relapsed or refractory CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL).” Doxorubicin hydrochloride is also described as “injection, for intravenous use” and is indicated for “acute lymphoblastic leukemia,” including use “as a component of multi-agent adjuvant chemotherapy.” The documents do not provide information on oral therapies, pharmacy-benefit dispensing, medical-benefit adjudication practices, or how benefit-routing ambiguities affect line-of-therapy construction in U.S. claims data. The documents identify oral maintenance-regimen therapies for Acute Lymphoblastic Leukemia (ALL), specifically mercaptopurine oral suspension and methotrexate tablets, which implies pharmacy-dispensed oral agents rather than infused medical-benefit products. Mercaptopurine is described as "MERCAPTOPURINE oral suspension" with dosing "orally once daily as part of a combination chemotherapy maintenance regimen." Methotrexate is described as "METHOTREXATE tablets, for oral use" and is indicated for "treatment of adults and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen." The supplied documents do not discuss United States claims adjudication, pharmacy versus medical benefit routing rules, dual-channel billing, infused agents, or line-of-therapy construction ambiguities, so those aspects cannot be determined from the provided evidence. The supplied documents identify multiple Acute Lymphoblastic Leukemia therapies and regimen components through HCPCS injection or CAR-T procedure codes, which indicates adjudication in claims systems tied to HCPCS-coded administration. Documented HCPCS-coded agents include rituximab, blinatumomab, inotuzumab ozogamicin, vincristine sulfate, doxorubicin hydrochloride, cyclophosphamide, methotrexate sodium, cytarabine, daunorubicin hydrochloride, tisagenlecleucel, and brexucabtagene autoleucel. The documents also show CAR-T products billed with HCPCS Q-codes that include administration-related language such as “including leukapheresis and dose preparation procedures, per infusion” and “per therapeutic dose.” The documents do not describe pharmacy-benefit therapies, oral agents, dual-channel billing, or routing ambiguities affecting line-of-therapy construction. The documents identify several Acute Lymphoblastic Leukemia therapies and products that appear in HCPCS and FDA product listings, including blinatumomab (Blincyto), inotuzumab ozogamicin (Besponsa), tisagenlecleucel (Kymriah), brexucabtagene autoleucel (Tecartus), and obecabtagene autoleucel (Aucatzyl). The HCPCS entries for obecabtagene autoleucel describe administration-linked billing constructs such as “including leukapheresis and dose preparation procedures” and billing “per therapeutic dose” or “per infusion,” which indicates medical-claim routing through HCPCS-coded services. However, the supplied documents do not state which therapies are adjudicated under the pharmacy benefit versus the medical benefit, do not describe oral versus infused benefit routing, and do not discuss dual-channel billing patterns or line-of-therapy construction ambiguities. The supplied documents identify some Acute Lymphoblastic Leukemia therapies as oral tablet products, including imatinib mesylate and ponatinib (ICLUSIG). Imatinib mesylate is described as “tablets, for oral use” and includes indications for “Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL)” and “Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy.” ICLUSIG is identified as “TABLET ORAL” in multiple strengths. However, the documents do not discuss United States claims adjudication under pharmacy versus medical benefits, do not describe infused versus medically billed agents, and do not address dual-channel billing patterns, routing ambiguities, or line-of-therapy construction issues. The documents identify several Acute Lymphoblastic Leukemia (ALL) therapies as oral tablet products, which in claims practice could correspond to pharmacy-dispensed agents, but the documents do not explicitly discuss pharmacy versus medical benefit adjudication. The ALL-related oral agents named are methotrexate tablets, imatinib mesylate tablets, and dasatinib tablets. The documents also reference use "in combination with chemotherapy" or as part of a "combination chemotherapy maintenance regimen," indicating that oral agents may be combined with other chemotherapy components, but they do not specify whether those accompanying chemotherapy agents are infused, medically billed, dual-channeled, or associated with routing ambiguities affecting line-of-therapy construction. The supplied documents identify several Acute Lymphoblastic Leukemia (ALL) therapies and regimen components, but they do not describe United States claims adjudication under pharmacy versus medical benefits or line-of-therapy routing logic. The documents do show that Methotrexate for ALL is provided as an injectable therapy and may involve intramuscular, subcutaneous, intravenous, or intrathecal administration, while also noting that patients may switch between oral and injectable methotrexate formulations. The documents also describe TECARTUS (brexucabtagene autoleucel) as a "single dose" CAR-T cell therapy. No document discusses dual-channel billing, pharmacy-benefit claims, medical-benefit claims, or benefit-routing ambiguities affecting line-of-therapy construction. The documents identify both oral and intravenous ALL therapies, which are relevant to potential pharmacy-versus-medical benefit routing, but they do not directly describe United States claims adjudication practices, dual-channel billing, or line-of-therapy construction rules. IMKELDI is described as an "SOLUTION ORAL," while nelarabine/Arranon are described as "injection" products for "intravenous use," including dosing administered "intravenously over" specified time periods. The supplied documents do not state whether these products are typically processed under pharmacy or medical benefits, and they do not discuss routing ambiguities or dual-channel billing patterns. The supplied documents identify several Acute Lymphoblastic Leukemia therapies as intravenous injectable products, which implies administration in a clinical setting but does not explicitly discuss United States claims adjudication under pharmacy versus medical benefits. Clofarabine is repeatedly described as an "injection" administered "as an intravenous infusion," and ARRANON is listed as an "INJECTABLE INTRAVENOUS" product. The documents do not provide information about pharmacy-benefit therapies, dual-channel billing, oral-versus-infused routing distinctions in claims systems, or benefit-routing ambiguities affecting line-of-therapy construction. The documents identify several Acute Lymphoblastic Leukemia therapies and their coding or dosage-form characteristics, but they do not directly state whether they are adjudicated under the pharmacy benefit or medical benefit in U.S. claims data, nor do they describe line-of-therapy routing ambiguities. Imatinib appears in HCPCS coding as "HCPCS code S0088," while ponatinib (Iclusig) is described as an oral "TABLET, FILM COATED ORAL" product in FDA NDC records. The supplied documents do not discuss dual-channel billing patterns, infused versus physician-administered adjudication, or benefit-routing ambiguities affecting line-of-therapy construction. The supplied document identifies therapies and regimen components used in Acute Lymphoblastic Leukemia treatment studies, including “BESPONSA,” “fludarabine + cytarabine + granulocyte colony-stimulating factor flag,” “mitoxantrone + cytarabine mxn/ara-c,” and “high dose cytarabine hidac.” The document also describes that patients received “treatment cycles” and compares “BESPONSA” with “Investigator’s choice of chemotherapy.” However, the document does not discuss United States claims adjudication, pharmacy versus medical benefit routing, oral versus infused benefit handling, dual-channel billing, or line-of-therapy construction ambiguities. The supplied documents identify Acute Lymphoblastic Leukemia therapies that are administered as intravenous injections or infusions, including clofarabine and nelarabine. Clofarabine is described as an “INJECTION INTRAVENOUS” product and its labeling states it is administered “as an intravenous infusion over 2 hours daily for 5 consecutive days.” Nelarabine (Arranon) is also described as an “INJECTION INTRAVENOUS” product. The documents do not provide information about adjudication under pharmacy versus medical benefits, dual-channel billing, oral versus infused benefit routing distinctions, or claims-based line-of-therapy ambiguities. The supplied documents identify doxorubicin as a therapy used for "acute lymphoblastic leukemia" and repeatedly describe it as being administered intravenously, including "given intravenously every 21 days," "administered as an intravenous bolus," and "Administration by Intravenous Injection." These documents therefore support that doxorubicin is an infused or injected regimen component rather than an oral agent. The documents identify several Acute Lymphoblastic Leukemia therapies through HCPCS billing codes that are associated with administered products typically appearing in medical claims. HCPCS code C9073 and HCPCS code Q2053 are both defined for "Brexucabtagene autoleucel" and include "leukapheresis and dose preparation procedures, per therapeutic dose," while HCPCS code J9039 is defined as "Injection, blinatumomab, 1 microgram." The supplied documents do not describe pharmacy-benefit adjudication, oral therapies, dual-channel billing, or benefit-routing ambiguities affecting line-of-therapy construction. The supplied documents identify dasatinib products as oral tablet formulations, including "Product: Dasatinib (dasatinib) TABLET ORAL" and "Product: SPRYCEL (dasatinib) TABLET ORAL." However, the documents do not state whether these therapies are adjudicated under the pharmacy benefit or the medical benefit, and they do not describe dual-channel billing, infused agents, regimen-component routing, or line-of-therapy construction ambiguities. No information is provided about medical-benefit therapies, oral-versus-infused adjudication rules, or benefit-routing patterns in claims data. The documents identify certain Acute Lymphoblastic Leukemia therapies as HCPCS-coded injectable products, which are typically represented in medical claims data. Specifically, HCPCS code J9229 is defined as "Injection, inotuzumab ozogamicin, 0.1 mg," HCPCS code C9028 is also defined as "Injection, inotuzumab ozogamicin, 0.1 mg," and HCPCS code C9449 is defined as "Injection, blinatumomab, 1 mcg." The supplied documents do not discuss pharmacy-benefit adjudication, oral therapies, dual-channel billing, benefit-routing ambiguities, or impacts on line-of-therapy construction. The supplied documents identify dasatinib products as oral tablet therapies, which implies they are dispensed products rather than infused agents. The records state "Product: SPRYCEL (dasatinib) TABLET ORAL" and "Product: Dasatinib (dasatinib) TABLET, FILM COATED ORAL." However, the documents do not discuss United States claims adjudication under pharmacy versus medical benefits, do not identify medical-benefit therapies, and do not describe dual-channel billing patterns, routing ambiguities, or impacts on line-of-therapy construction. The supplied documents identify oral ALL-related therapies that would typically appear as pharmacy-dispensed products because they are described as oral tablets or oral solution products with NDC packaging. Ponatinib (Iclusig) is listed as a "TABLET, FILM COATED ORAL" product in bottle packaging, and imatinib (IMKELDI) is listed as a "SOLUTION ORAL" product. The documents do not describe any infused therapies, medical-benefit adjudication, dual-channel billing, or benefit-routing ambiguities affecting line-of-therapy construction. The supplied documents identify dasatinib/SPRYCEL as an oral tablet product, which is relevant to pharmacy-versus-medical benefit routing because the products are described as "TABLET ORAL." Specifically, the documents describe both branded SPRYCEL and generic dasatinib oral tablet formulations. However, the documents do not describe United States claims adjudication practices, pharmacy benefit versus medical benefit assignment, dual-channel billing, infused therapies, regimen components, or line-of-therapy routing ambiguities. The supplied documents identify dasatinib formulations that are "TABLET, FILM COATED ORAL," which indicates an oral therapy form relevant to Acute Lymphoblastic Leukemia treatment claims. However, the documents do not describe whether therapies are adjudicated under the pharmacy benefit or medical benefit, do not discuss infused agents, and do not provide information on dual-channel billing patterns, routing ambiguities, or line-of-therapy construction rules in United States claims data.

The supplied documents identify some supportive or prophylactic agents associated with acute lymphoblastic leukemia care, but they do not provide a comprehensive exclusion list for regimen identification or line-of-therapy assignment in United States claims analyses. The documents mention prophylactic anticoagulation and supportive growth-factor use: in ALL, "Low-molecular-weight heparins (LMWH) at prophylactic doses are recommended as the first-line strategy" and "Direct oral anticoagulants (DOACs) may be considered" in selected situations; in leukemia supportive care, LEUKINE is described as "a leukocyte growth factor indicated" "To shorten time to neutrophil recovery and to reduce the incidence of severe and life-threatening infections." The documents also reference transfusion support through measures such as "platelet (>20,000 cells/mm3) and RBC transfusion independence." No supplied document addresses anti-infective prophylaxis agents, antiemetics, rescue agents, tumor lysis management drugs, or explicit non-therapeutic exclusions for claims-based regimen construction. The supplied documents mention supportive care in acute lymphoblastic leukemia guidelines, but they do not enumerate specific supportive-care, prophylactic, rescue, adjunctive, transfusion, tumor lysis, antiemetic, anti-infective, growth factor, or non-therapeutic agents that should be excluded from regimen identification or line-of-therapy assignment in United States claims analyses. One document states that the NCCN guidelines include “guidance on supportive care,” and another refers to “enhanced supportive care,” but neither provides the requested exclusion lists or agent names. The supplied document indicates that ALL guidelines include “supportive care considerations,” but it does not specify which supportive-care, prophylactic, rescue, adjunctive, or non-therapeutic agents should be excluded from regimen identification or line-of-therapy assignment in United States claims analyses. The document also does not provide lists covering anti-infective prophylaxis, growth factor support, antiemetics, tumor lysis management, transfusion support, or non-therapeutic exclusions. The supplied documents indicate that NCCN Acute Lymphoblastic Leukemia guidelines include “supportive care considerations,” but they do not enumerate specific supportive-care, prophylactic, rescue, adjunctive, transfusion, tumor-lysis, antiemetic, growth-factor, anti-infective, or non-therapeutic agents to exclude from regimen identification or line-of-therapy assignment in claims analyses. No document provides a list of medications or coding exclusions for treatment sequencing analyses.

The supplied documents identify methotrexate-containing therapies used in Acute Lymphoblastic Leukemia (ALL), including oral tablets, injectable products, and an oral solution, but they do not provide representative NDC identifiers, biosimilar relationships, or a complete exhaustive pull methodology. The Bryant Ranch Prepack labeling states that “Methotrexate tablets are a dihydrofolate reductase inhibitor indicated for the: • Treatment of adults and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen,” while the Hospira Drugs@FDA entry enumerates multiple injectable package presentations and strengths such as “METHOTREXATE SODIUM PRESERVATIVE FREE INJECTABLE INJECTION strength EQ 1GM BASE/40ML (EQ 25MG BASE/ML)” and “METHOTREXATE SODIUM INJECTABLE INJECTION strength EQ 50MG BASE/2ML (EQ 25MG BASE/ML).” Manufacturer or sponsor mapping is partially available because the sources are identified as “HOSPIRA,” “Bryant Ranch Prepack,” and “SHORLA ONCOLOGY,” and the IMKELDI entry states “Application: NDA219097 sponsored by SHORLA ONCOLOGY.” The documents also support multi-source generic considerations for methotrexate because multiple formulations and manufacturers are represented, including discontinued and prescription injectable products under the same active ingredient. The supplied documents identify some principal Acute Lymphoblastic Leukemia (ALL) therapies and classes used in treatment recommendations, but they do not provide the requested exhaustive United States claims-based drug identification universe elements such as NDC identifiers, manufacturer/labeler mappings, package presentations, biosimilar relationships, or multi-source generic logic. The NCCN guideline states that the ALL guidelines focus on “treatment strategies for Philadelphia chromosome (Ph)-positive and Ph-negative ALL,” while another document states that “Asparaginase is an integral component of therapy for pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma.” One FDA labeling document states that “DOXOrubicin HCl Injection, USP and DOXOrubicin HCl for Injection, USP have been used successfully to produce regression in disseminated neoplastic conditions such as acute lymphoblastic leukemia.” However, none of the supplied documents contain representative NDCs, package presentations, manufacturer or labeler mappings, biosimilar relationships, or exhaustive pull methodologies for claims data extraction. The documents identify several principal Acute Lymphoblastic Leukemia (ALL) therapies and provide limited NDC, manufacturer/labeler, package, and coding details. The only explicit NDC/package/manufacturer mapping provided is for IMKELDI: "NDC 81927-201: IMKELDI" from "Shorla Oncology Inc." with packaging "140 mL in 1 BOTTLE (81927-201-01)" and active ingredient "IMATINIB MESYLATE 80 mg/mL." BLINCYTO is identified as "BLINCYTO (BLINATUMOMAB) KIT [AMGEN, INC]" and described as indicated for "B-cell precursor acute lymphoblastic leukemia (ALL)." CMS HCPCS release data additionally identify claims-relevant agents including blinatumomab, inotuzumab ozogamicin, rituximab, vincristine sulfate, doxorubicin hydrochloride, cyclophosphamide, methotrexate sodium, cytarabine, daunorubicin hydrochloride, tisagenlecleucel, and brexucabtagene autoleucel, but the supplied documents do not provide exhaustive NDC universes, biosimilar relationships, or multi-source generic mappings through 2026-09-21. The documents identify dasatinib/SPRYCEL as a principal Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) therapy and provide manufacturer or labeler names plus dosage-form strengths, but they do not provide explicit NDC identifiers, package presentations, biosimilar relationships, or exhaustive multi-source generic pull methodology. The branded product is "SPRYCEL" sponsored by "BRISTOL MYERS SQUIBB," with oral tablet strengths of "20MG," "50MG," "70MG," "80MG," "100MG," and "140MG." Generic labeling is also documented for "Dasatinib tablets" from "BluePoint Laboratories" and "Biocon Pharma Limited," and another SPRYCEL label references "Physicians Total Care, Inc." The supplied records support inclusion of branded and generic dasatinib products in a claims-based drug universe for Ph+ ALL, but the documents do not contain the exhaustive NDC-level inventory, package configurations, biosimilar mappings, or generic sourcing rules requested. The supplied documents identify representative NDCs, labelers/manufacturers, package presentations, and marketing categories for selected Acute Lymphoblastic Leukemia therapies, specifically Iclusig (ponatinib hydrochloride) and generic dasatinib products from Biocon Pharma Inc. Takeda Pharmaceuticals America, Inc. markets Iclusig under NDC 63020-535 with bottle presentations containing 30 or 60 film-coated tablets, while Biocon Pharma Inc. markets dasatinib ANDA products under NDCs 70377-083 and 70377-085 with 60-tablet bottle presentations at 20 mg and 70 mg strengths respectively. The documents support that dasatinib products are marketed under ANDA, which is relevant to multi-source generic considerations, whereas Iclusig is marketed under NDA. The documents do not provide biosimilar relationships, a complete ALL therapy universe, exhaustive pull methodology, or broader manufacturer-labeler mappings beyond the cited products. The supplied documents identify several Acute Lymphoblastic Leukemia-related therapies and their manufacturers or labelers, but they do not provide NDC identifiers, package presentations, biosimilar relationships, multi-source generic considerations, or an exhaustive pull methodology. The documents identify “KYMRIAH (TISAGENLECLEUCEL) INJECTION, SUSPENSION novartis pharmaceuticals corporation”, “TECARTUS (BREXUCABTAGENE AUTOLEUCEL) SUSPENSION [KITE PHARMA, INC.]”, and “NELARABINE (NELARABINE)” from “Alembic Pharmaceuticals Limited”. The Nelarabine labeling specifically states that “Nelarabine injection is indicated for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL)”. No supplied document contains representative NDCs, manufacturer-labeler crosswalks beyond the label names, package configurations, biosimilar mappings, or generic universe construction rules. The supplied documents identify imatinib mesylate as a therapy used for Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL), including "Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL)" and "Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy." The documents also identify multiple labelers or sources for the same product labeling, including "Apotex Corp," "Sun Pharmaceutical Industries, Inc.," and "US Food and Drug Administration (FDA Drug Labeling (openFDA), tier 1)." However, the documents do not provide NDC identifiers, package presentations, biosimilar relationships, multi-source generic considerations, or an exhaustive pull methodology for claims-based drug identification universes through 2026-09-21. The supplied documents identify several principal Acute Lymphoblastic Leukemia therapies and certain biosimilar relationships from the FDA Purple Book, including Rituxan/rituximab, Blincyto/blinatumomab, Besponsa/inotuzumab ozogamicin, Kymriah/tisagenlecleucel, Tecartus/brexucabtagene autoleucel, Aucatzyl/obecabtagene autoleucel, and the rituximab biosimilars Truxima, Ruxience, and Riabni. The documents also provide representative NDC identifiers, package presentations, and manufacturer/labeler information for authorized generic dasatinib products from Prasco Laboratories, specifically NDCs 66993-233-60 and 66993-234-60. However, the documents do not provide an exhaustive ALL claims-identification universe through 2026-09-21, do not enumerate all manufacturers/labelers or package configurations for the listed therapies, and do not describe a complete pull methodology. The supplied documents identify representative Acute Lymphoblastic Leukemia therapy products and their NDC/package/manufacturer mappings, including Iclusig (ponatinib hydrochloride), Arranon (nelarabine), and SPRYCEL (dasatinib). lists Iclusig under NDC 63020-536 with package presentation "30 TABLET, FILM COATED in 1 BOTTLE (63020-536-30)"; Novartis Pharmaceuticals Corporation lists Arranon under NDC 0078-0683 with package presentation "50 mL in 1 VIAL (0078-0683-61)"; and E.R. Squibb & Sons, L.L.C. lists SPRYCEL under NDC 0003-0855 with package presentation "1 BOTTLE in 1 CARTON (0003-0855-22) / 30 TABLET in 1 BOTTLE." The documents do not provide biosimilar relationships, multi-source generic considerations, or an exhaustive pull methodology, and they do not establish a complete ALL therapy universe through 2026-09-21. The documents identify two Acute Lymphoblastic Leukemia therapies and their sponsors/labelers, but they do not provide representative NDC identifiers, package presentations, biosimilar relationships, or exhaustive multi-source generic pull methodology. ICLUSIG is identified under "NDA203469 sponsored by TAKEDA PHARMS USA" with oral tablet products at strengths "EQ 10MG BASE," "EQ 45MG BASE," "EQ 30MG BASE," and "EQ 15MG BASE." Methotrexate Injection is identified from Hospira, Inc. labeling as indicated for "acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy regimen" and described as "for intravenous, intramuscular, subcutaneous, or intrathecal use." The supplied documents do not state any NDC numbers, package sizes, biosimilar relationships, interchangeable products, or generic universe methodology. The supplied documents identify Biocon Pharma Inc. as the labeler/manufacturer source for several dasatinib oral tablet NDCs relevant to Acute Lymphoblastic Leukemia claims identification. Representative NDCs include 70377-084-11 for 50 mg tablets packaged as "60 TABLET, FILM COATED in 1 BOTTLE," 70377-086-11 for 80 mg tablets packaged as "30 TABLET, FILM COATED in 1 BOTTLE," and 70377-087-11 for 100 mg tablets packaged as "30 TABLET, FILM COATED in 1 BOTTLE." All listed products are marketed under the "ANDA" category, which indicates generic approval status in the FDA NDC Directory entries. The documents do not provide exhaustive ALL therapy coverage, biosimilar relationships, broader manufacturer mappings, or a complete pull methodology for claims-universe construction. The supplied documents identify Acute Lymphoblastic Leukemia (ALL) therapies including methotrexate and imatinib, but they do not provide an exhaustive U.S. claims-data drug identification universe through 2026-09-21. The documents show that methotrexate tablets from multiple manufacturers are indicated for “acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen,” demonstrating a multi-source generic situation across at least Alembic Pharmaceuticals and Aurobindo Pharma. The HCPCS material also identifies imatinib under HCPCS code S0088 as “Imatinib 100 mg — Imatinib, 100 mg.” However, the documents do not provide representative NDC identifiers, package presentations, biosimilar relationships, or exhaustive pull methodology. The supplied documents identify representative NDCs for ALL-related kinase inhibitor therapies including Dasatinib and Iclusig/Ponatinib products. Biocon Pharma Inc. markets an ANDA dasatinib product under NDC 70377-088 with package presentation "30 TABLET, FILM COATED in 1 BOTTLE (70377-088-11)" and active ingredient strength "DASATINIB 140 mg/1." Takeda Pharmaceuticals America, Inc. markets Iclusig (ponatinib hydrochloride) NDA products under NDCs 63020-533 and 63020-534, each packaged as "30 TABLET, FILM COATED in 1 BOTTLE" with strengths "30 mg/1" and "45 mg/1" respectively. The documents do not provide biosimilar relationships, broader multi-source generic considerations, or an exhaustive pull methodology for claims-based drug identification universes. The supplied documents identify doxorubicin products used for Acute Lymphoblastic Leukemia treatment indications, including branded and generic presentations such as “Doxorubicin Hydrochloride Injection,” “Adriamycin (DOXOrubicin HCl) for Injection, USP,” and “Adriamycin (DOXOrubicin HCl) Injection, USP.” The documents also provide limited package presentation details through vial strengths and reconstitution instructions, including “10 mg doxorubicin HCl vial” and “50 mg doxorubicin HCl vial.” However, the documents do not provide NDC identifiers, manufacturer-labeler crosswalks beyond Pfizer and FDA SPL references, biosimilar relationships, multi-source generic methodology, or exhaustive claims pull methodology for ALL therapies through 2026-09-21. The supplied documents identify clofarabine injection as an Acute Lymphoblastic Leukemia therapy and show multiple manufacturers/labelers associated with the product, including Amneal Pharmaceuticals, Ingenus Pharmaceuticals, LLC, and Dr. Reddy’s Laboratories Inc. The documents consistently state that clofarabine injection is indicated "for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens." However, the documents do not provide NDC identifiers, package presentations, biosimilar relationships, multi-source generic considerations, or an exhaustive pull methodology for United States claims data through 2026-09-21. The supplied documents identify several Acute Lymphoblastic Leukemia (ALL) therapies and limited coding/manufacturer information, but they do not provide an exhaustive U.S. claims-based drug identification universe through 2026-09-21. The documents identify blinatumomab through HCPCS code C9449, ARRANON (nelarabine) with sponsor/manufacturer SANDOZ and injectable presentation strength, and mercaptopurine oral suspension indicated for ALL maintenance therapy. However, the documents do not provide representative NDC identifiers, complete manufacturer or labeler mappings, package presentations across products, biosimilar relationships, multi-source generic mappings, or an exhaustive pull methodology. The supplied documents identify HCPCS-coded ALL cellular therapies relevant to claims identification, specifically tisagenlecleucel, brexucabtagene autoleucel, and obecabtagene autoleucel. The documents provide HCPCS identifiers and therapy descriptions including therapeutic-dose definitions and leukapheresis/dose preparation inclusion, but they do not provide NDC identifiers, manufacturers or labelers, package presentations, biosimilar relationships, multi-source generic considerations, or an exhaustive pull methodology. The available claims-identification details are HCPCS Q2042 for tisagenlecleucel, HCPCS C9073 for brexucabtagene autoleucel, and HCPCS C9301 for obecabtagene autoleucel. The supplied documents provide only a limited subset of an Acute Lymphoblastic Leukemia (ALL) drug-identification universe. They identify a generic clofarabine injection from Dr. Reddy’s Laboratories with NDC 43598-309-20 and an NDA nelarabine product (Arranon) from Sandoz with NDC 66758-165-94, including package presentations and marketing categories. The documents also identify BESPONSA (inotuzumab ozogamicin) as indicated for relapsed or refractory CD22-positive B-cell precursor ALL, but they do not provide NDCs, package configurations, biosimilar relationships, exhaustive manufacturer mappings, or a comprehensive pull methodology for all principal ALL therapies through 2026-09-21. The supplied documents identify representative NDCs for SPRYCEL (dasatinib) oral tablets from E.R. Squibb & Sons, L.L.C., including NDCs 0003-0528, 0003-0524, and 0003-0857. Package presentations include 60-tablet bottles and 30-tablet bottles packaged as "1 BOTTLE in 1 CARTON," with strengths of 50 mg, 70 mg, and 140 mg respectively. All listed products have marketing category "NDA" and marketing start dates ranging from 2006-06-27 to 2010-10-28. The documents do not provide biosimilar relationships, multi-source generic considerations, broader ALL therapy coverage, or an exhaustive pull methodology for claims-based drug identification through 2026-09-21. The supplied documents identify HCPCS-coded Acute Lymphoblastic Leukemia therapies but do not provide NDC identifiers, manufacturer or labeler mappings, package presentations, biosimilar relationships, multi-source generic considerations, or an exhaustive pull methodology. The documents identify HCPCS code J9229 for inotuzumab ozogamicin, HCPCS code Q2040 for tisagenlecleucel, and HCPCS code Q2053 for brexucabtagene autoleucel. Because the documents are limited to HCPCS descriptions, the requested exhaustive drug identification universe for United States claims data through 2026-09-21 cannot be fully constructed from the supplied evidence. The supplied documents identify several Acute Lymphoblastic Leukemia-related HCPCS therapy codes and their drug descriptions, but they do not provide NDC identifiers, manufacturers or labelers, package presentations, biosimilar relationships, multi-source generic considerations, or exhaustive pull methodology. The documents identify HCPCS code Q2058 for obecabtagene autoleucel, HCPCS code J9039 for blinatumomab, and HCPCS code C9028 for inotuzumab ozogamicin. No document contains representative NDCs, package configurations, manufacturer mappings, biosimilar linkage data, or generic sourcing considerations. The supplied documents identify several principal Acute Lymphoblastic Leukemia (ALL) therapies relevant to relapsed/refractory or pediatric ALL treatment contexts, including “blinatumomab,” “inotuzumab,” and “PEGasparaginase.” However, the documents do not provide any NDC identifiers, manufacturer or labeler mappings, package presentations, biosimilar relationships, multi-source generic considerations, or exhaustive claims-based pull methodologies. Therefore, an exhaustive United States claims-data drug identification universe through 2026-09-21 cannot be constructed from these documents alone.

The documents provide limited dosing and administration details for some therapies used in acute lymphoblastic leukemia (ALL), but they do not comprehensively describe all principal ALL therapies, complete cycle structures, or line-of-therapy identification patterns through 2026-09-21. For mercaptopurine used in ALL maintenance therapy, the labeling states that the "recommended starting dose of mercaptopurine oral suspension is 1.5 mg/kg to 2.5 mg/kg (50 mg/m 2 to 75 mg/m 2 ) orally once daily as part of combination chemotherapy maintenance regimen," with dose adjustment based on neutrophil counts and myelosuppression. The same source specifies administration considerations including oral suspension handling, dosing interval adjustments in renal impairment, and administration instructions. For imatinib in relapsed or refractory Philadelphia chromosome positive ALL, the document confirms the indication in adult patients but does not provide ALL-specific dosing schedules or cycle structures. The asparaginase consensus document states that "asparaginase is an integral component of therapy" in pediatric-inspired regimens for AYA and adult ALL populations and discusses administration barriers including "limited medical facilities and experienced staff to administer and manage pediatric-inspired regimens," but it does not provide standard adult dosing or schedules. The supplied documents describe administration and dosing patterns for select relapsed/refractory ALL therapies used in U.S. practice, including CAR-T products and nelarabine. TECARTUS for adult relapsed/refractory B-cell precursor ALL is administered intravenously after lymphodepleting chemotherapy, with a target dose of "1 × 10 6 CAR-positive viable T cells per kg body weight, with a maximum of 1 × 10 8 CAR-positive viable T cells," and requires premedication, identity verification, and tocilizumab availability before infusion. Nelarabine for relapsed/refractory T-ALL/T-LBL in adults is given as "1,500 mg/m² administered intravenously over 2 hours on Days 1, 3, and 5 repeated every 21 days," with discontinuation for neurologic toxicity grade 2 or greater and possible dose delays for hematologic reactions. KYMRIAH is identified as a CD19-directed autologous T-cell immunotherapy for "patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse," administered as an "intravenous infusion," but the supplied excerpt does not provide detailed adult ALL dosing schedules because the indication is pediatric/young adult only. The documents provide limited dosing and administration information for therapies used in Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL), specifically imatinib and dasatinib product identification. Imatinib mesylate is indicated for “Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL)” and for “Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy.” The supplied text does not provide adult ALL-specific standard dosing schedules, cycle structures, or administration setting guidance for imatinib, but it does describe oral daily dosing patterns in related leukemia studies: “patients were treated initially with 400 mg daily” with “Dose escalations ... from 400 mg daily to 600 mg daily, then from 600 mg daily to 800 mg daily.” For dasatinib (SPRYCEL), the documents identify the dosage forms and oral route through “SPRYCEL TABLET ORAL” products with strengths including “20MG,” “50MG,” “70MG,” “80MG,” “100MG,” and “140MG,” but no ALL-specific dosing schedules or regimen structures are provided. The supplied documents provide dosing and administration details only for clofarabine in relapsed/refractory acute lymphoblastic leukemia, and specifically state that it is indicated for pediatric patients rather than all adult ALL therapies used in U.S. practice. Clofarabine is described as being administered "52 mg/m 2 as an intravenous infusion over 2 hours daily for 5 consecutive days of a 28-day cycle," with cycles repeated "approximately every 2 to 6 weeks" and subsequent cycles given "no sooner than 14 days from the starting day of the previous cycle and provided the patient’s ANC is ≥ 0.75 × 10 9 /L." The documents also describe claim-relevant administration considerations including supportive care with "intravenous fluids, antihyperuricemic treatment, and alkalinize urine," avoidance of administering other medications through the same IV line, monitoring during administration, and renal dose reduction "by 50% in patients with creatinine clearance (CrCL) between 30 mL/min and 60 mL/min." No standard adult dosing patterns, adult line-of-therapy structures, or comprehensive ALL regimens through 2026-09-21 are provided in the supplied records. The documents identify methotrexate as a therapy used in acute lymphoblastic leukemia (ALL) and state that it is administered as part of combination chemotherapy regimens, but they do not provide complete adult ALL regimen dosing schedules or cycle structures. The methotrexate labeling states that for neoplastic diseases clinicians should "Refer to the prescribing information for disease specific dosing recommendations" and that "Methotrexate Injection is used as part of a multi-drug regimen." Administration considerations for intermediate- and high-dose methotrexate include leucovorin rescue, daily monitoring, intravenous fluids, urine alkalinization, and glucarpidase use for toxic plasma concentrations with delayed clearance. The NCCN guideline excerpt states that ALL treatment recommendations include "risk-stratified treatment approaches" and that "patients be treated at specialized centers with expertise in the management of ALL." A claim-relevant cellular therapy code is also identified for tisagenlecleucel as "up to 600 million car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose." The supplied documents provide limited information on dosing patterns and administration considerations for certain Acute Lymphoblastic Leukemia therapies, but they do not comprehensively describe standard adult regimens, cycle structures, or line-of-therapy identification used in United States clinical practice through 2026-09-21. For PEGasparaginase in ALL11 protocol patients, the documents state that “After the 3 doses of 1500 IU/m 2 administered in induction, standard-risk patients received 1 individualized dose and medium-risk patients 14,” and also describe a “continuous PEGasparaginase dosing schedule” with individualized dose reductions targeting trough activity levels. For CAR-T cell therapy in relapsed/refractory B-ALL, the documents describe the “bridging period between leukapheresis and CAR-T-cells reinfusion” as a treatment consideration but explicitly note that “there is currently no available guidelines.” For nelarabine (Arranon), the documents identify the product as “INJECTION INTRAVENOUS” with active ingredient concentration “NELARABINE 5 mg/mL,” but no adult dosing schedule or cycle information is provided. The documents provide adult dosing and administration information for doxorubicin used in acute lymphoblastic leukemia, but they do not comprehensively enumerate all principal ALL therapies used in United States clinical practice through 2026-09-21. For doxorubicin, the labeling states that for “Metastatic Disease, Leukemia, or Lymphoma” the “recommended dose of doxorubicin when used as a single agent is 60 to 75 mg/m 2 intravenously every 21 days,” and “when administered in combination with other chemotherapy drugs, is 40 to 75 mg/m 2 intravenously every 21 to 28 days.” Administration guidance specifies intravenous administration, including that clinicians should “Administer doxorubicin intravenously over 3 to 10 minutes” through “a central intravenous line or a secure and free-flowing peripheral venous line.” The documents also include claim-relevant cycle and exposure considerations such as “Cumulative doses above 550 mg/m 2 are associated with an increased risk of cardiomyopathy” and that lower doses or longer intervals may be considered for “heavily pretreated patients, elderly patients, or obese patients.” The supplied documents only partially address adult therapy administration patterns for Acute Lymphoblastic Leukemia (ALL) in U.S. For Philadelphia chromosome-positive (Ph+ ALL), the FDA labeling states that SPRYCEL (dasatinib) is indicated for “adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy,” and trial dosing exposures included “starting dosage 100 mg once daily, 140 mg once daily, 50 mg twice daily, or 70 mg twice daily.” The labeling also reports treatment duration information for lymphoid blast disease, including that “the median duration of treatment with SPRYCEL 140 mg once daily was ... 3 months (range 0.1–10 months) for lymphoid blast CML.” Separately, HCPCS coding documentation identifies blinatumomab as an injectable therapy using “HCPCS code J9039” defined as “Injection, blinatumomab, 1 microgram.” The documents do not provide complete standard adult dosing schedules, cycle structures, routes, line-of-therapy algorithms, or administration-setting details for the principal ALL regimens used through 2026. The supplied documents identify limited administration and claim-relevant information for Acute Lymphoblastic Leukemia (ALL) therapies, but they do not provide comprehensive standard adult dosing patterns, schedules, or cycle structures through 2026-09-21. Methotrexate Injection is indicated for ALL "as part of a combination chemotherapy regimen" and is labeled "for intravenous, intramuscular, subcutaneous, or intrathecal use," with additional administration considerations including preservative-free formulations for intrathecal use and restrictions related to benzyl alcohol-containing formulations. Brexucabtagene autoleucel HCPCS entries describe a "per therapeutic dose" administration with "up to 200 million autologous anti-cd19 car positive viable t cells" and include "leukapheresis and dose preparation procedures," which are claim-relevant administration components. The documents do not provide standard adult dose amounts, treatment schedules, line-of-therapy definitions, or cycle timing structures for these therapies. The documents identify several therapies used in Acute Lymphoblastic Leukemia and provide limited administration-related information through HCPCS descriptors and one FDA label, but they do not provide comprehensive standard adult dosing, schedules, or cycle structures. HCPCS files identify injectable products including blinatumomab, inotuzumab ozogamicin, vincristine sulfate, doxorubicin hydrochloride, cyclophosphamide, methotrexate sodium, cytarabine, daunorubicin hydrochloride, rituximab, and CAR-T products including tisagenlecleucel and brexucabtagene autoleucel. The dasatinib label states that "DASATINIB tablets, for oral use" are indicated for "Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy." CAR-T administration considerations are partially described because tisagenlecleucel HCPCS language specifies "including leukapheresis and dose preparation procedures, per infusion," and brexucabtagene autoleucel is described as "per therapeutic dose." The supplied documents identify doxorubicin as a therapy used in acute lymphoblastic leukemia and provide adult dosing, administration route, schedules, and some administration considerations, but they do not comprehensively cover all principal therapies used in United States clinical practice through 2026-09-21. For leukemia or lymphoma, doxorubicin is described as a single agent at "60 to 75 mg/m 2 intravenously every 21 days" or in combination therapy at "40 to 75 mg/m 2 intravenously every 21 to 28 days." Administration details include intravenous injection through "a central intravenous line or a secure and free-flowing peripheral venous line," with administration "over 3 to 10 minutes," and continuous infusion "only through a central catheter." The documents also describe cycle structure and claim-relevant modifications, including treatment on "day 1 of each 21 day treatment cycle" for "a total of four cycles," dose reductions for hepatic impairment, and cycle delays until recovery of blood counts. The supplied documents identify only limited therapy and administration information for acute lymphoblastic leukemia (ALL). Methotrexate tablets are indicated for “treatment of adults and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen,” and the formulation is specified as “METHOTREXATE tablets, for oral use.” The ASH 2026 guideline document for relapsed/refractory ALL states that recommendations “focused on the following treatment modalities: immunotherapy, targeted therapies, allogeneic hematopoietic stem cell transplant, and central nervous system (CNS)-directed therapy,” and that “Key recommendations include the use of blinatumomab and/or inotuzumab over chemotherapy for reinduction.” However, the documents do not provide standard adult dosing, administration schedules, cycle structures, or detailed claim-relevant dosing patterns through 2026-09-21. The supplied documents do not provide standard adult dosing, administration routes, schedules, cycle structures, or detailed claim-relevant administration patterns for principal acute lymphoblastic leukemia therapies in United States clinical practice through 2026-09-21. The documents do state that treatment regimens differ between pediatric-inspired and adult-inspired approaches, and that pediatric-inspired regimens containing asparaginase are recommended frontline therapy for adolescents and young adults. The materials also note supportive care requirements, use of targeted agents in frontline therapy, and consideration of allogeneic hematopoietic stem cell transplantation in selected higher-risk patients, but they do not specify drug-level dosing schedules or administration details needed for regimen identification from claims. The supplied documents provide claim-relevant adult dosing, administration route, schedule, cycle structure, and administration-setting considerations for blinatumomab (BLINCYTO) and inotuzumab ozogamicin (BESPONSA) used in acute lymphoblastic leukemia. BLINCYTO is administered intravenously and includes hospitalization and steroid premedication requirements tied to treatment cycles for MRD-positive and relapsed/refractory B-cell precursor ALL. BESPONSA is administered by intravenous infusion with cycle-specific dosing on Days 1, 8, and 15, response-dependent cycle lengths, and mandatory corticosteroid, antipyretic, and antihistamine premedication. The documents do not provide comprehensive dosing and regimen details for all principal ALL therapies used in U.S. clinical practice through 2026-09-21. The documents identify certain Acute Lymphoblastic Leukemia (ALL) therapies and limited administration-related details, but they do not provide comprehensive adult regimen dosing, schedules, cycle structures, or line-of-therapy patterns through 2026-09-21. Blinatumomab and inotuzumab ozogamicin are identified in HCPCS coding as injectable products with billing units of "1 mcg" and "0.1 mg" respectively. Methotrexate tablets are identified for "treatment of adults and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen," but no ALL-specific adult maintenance dosing schedule, route timing, or cycle structure is provided in the supplied documents. The supplied documents identify several therapies used in Acute Lymphoblastic Leukemia (ALL), including methotrexate formulations, blinatumomab, inotuzumab ozogamicin, rituximab, tisagenlecleucel, brexucabtagene autoleucel, and obecabtagene autoleucel. The documents also mention transplantation approaches and post-transplant tyrosine kinase inhibitor maintenance strategies for Philadelphia chromosome positive ALL. However, the documents do not provide the requested standard adult dosing patterns, administration routes, treatment schedules, cycle structures, administration settings, or claim-relevant dosing details needed for regimen or line-of-therapy identification. The supplied documents identify HCPCS-coded therapies relevant to Acute Lymphoblastic Leukemia claims and provide limited administration-unit information, but they do not provide standard adult dosing patterns, schedules, cycle structures, line-of-therapy positioning, or administration-setting guidance. Inotuzumab ozogamicin is identified as an injectable product with HCPCS unit definition "0.1 mg." Obecabtagene autoleucel is identified as a CAR-positive viable T-cell therapy with dosing described as "up to 400 million cd19 car-positive viable t cells," including "leukapheresis and dose preparation procedures," and billed "per therapeutic dose" or "per infusion." The supplied documents identify several Acute Lymphoblastic Leukemia therapies and limited administration characteristics, but they do not provide standard adult dosing schedules, cycle structures, line-of-therapy rules, or administration-setting guidance. Iclusig (ponatinib hydrochloride) is described as an oral film-coated tablet with a 10 mg strength presentation, and SPRYCEL (dasatinib) is described as an oral tablet with a 140 mg strength presentation. The HCPCS entry identifies imatinib as "Imatinib 100 mg." No document provides treatment schedules, cycle timing, dose modifications, or claim-relevant regimen construction details. The supplied documents do not provide comprehensive United States adult ALL regimen details such as standard dosing, schedules, cycle structures, or administration-setting considerations. One FDA Drugs@FDA entry identifies ICLUSIG formulations and route relevant to ALL-related therapy identification: it lists "ICLUSIG TABLET ORAL" products with multiple strengths. A Chinese adult ALL guideline states that "systematic treatment regimens" and immunotherapies including antibodies and CAR-T products are used in adult ALL clinical practice, but it does not specify adult dosing patterns or cycle structures. The supplied documents identify dasatinib as an oral tablet product with multiple tablet strengths that may be relevant to Acute Lymphoblastic Leukemia regimen identification in claims data. The documents provide packaging, dosage strength, and oral route information for 20 mg, 50 mg, and 70 mg film-coated tablets. However, the documents do not provide standard adult dosing, treatment schedules, cycle structures, administration setting considerations, line-of-therapy usage, or claim-relevant dosing patterns for ALL treatment through 2026-09-21. The supplied documents identify dasatinib (SPRYCEL and generic dasatinib) as an oral tablet product used in U.S. practice, with available tablet strengths including 50 mg, 70 mg, and 140 mg. The documents also identify packaging quantities that may be relevant for claim-level regimen identification, including bottles containing 30 or 60 tablets. The supplied document identifies Arranon (nelarabine) as an intravenous injection product used in U.S. clinical practice packaging and formulation information. It specifies the formulation strength as "NELARABINE 5 mg/mL" and the administration route as "INJECTION INTRAVENOUS." The document does not provide standard adult dosing, treatment schedules, cycle structure, administration setting considerations, or claim-relevant dosing patterns for Acute Lymphoblastic Leukemia regimens or line-of-therapy identification. The supplied documents identify Iclusig (ponatinib hydrochloride) as an oral tablet product with multiple tablet strengths that could support claim-based identification of therapy exposure. The documents provide packaging and strength information for 15 mg, 30 mg, and 45 mg tablet presentations, but they do not provide standard adult dosing, treatment schedules, cycle structures, line-of-therapy positioning, or administration-setting considerations for Acute Lymphoblastic Leukemia treatment through 2026-09-21. The supplied documents identify dasatinib products used in U.S. practice for Acute Lymphoblastic Leukemia and establish oral tablet administration and available tablet strengths, but they do not provide standard adult dosing, treatment schedules, cycle structures, line-of-therapy use, or administration-setting considerations. The records show SPRYCEL and generic dasatinib as oral tablet products with 80 mg and 100 mg strengths packaged in bottles containing 30 tablets. The supplied documents identify certain Acute Lymphoblastic Leukemia therapies and their administration forms/routes, but they do not provide standard adult dosing, schedules, cycle structures, line-of-therapy use, or administration-setting considerations. Dasatinib is identified as an oral tablet product with strengths including 20 mg and 50 mg. Clofarabine is identified as an intravenous injection product with concentration 1 mg/mL in a single-dose vial. The supplied documents identify IMKELDI as an oral imatinib formulation relevant to leukemia treatment identification, but they do not provide standard adult dosing, schedules, cycle structures, line-of-therapy criteria, or administration setting considerations for Acute Lymphoblastic Leukemia. The documents only specify that IMKELDI is an "imatinib oral" "SOLUTION ORAL" product with strength "80 mg/mL" and marketing details for the United States.